New £9.1m contract with a top 10 global pharmaceutical company

Specialist medical imaging services for a Phase III Huntington’s disease clinical trial, highlighting the value of IXICO’s data science expertise in neuroscience drug development.

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announced that it has signed a new contract with a top 10 global pharmaceutical company, to provide its technology enabled imaging services in support of a Pivotal Phase III study in Huntington’s disease. The contract value of £9.1m will be delivered over a four year term.

As part of this study, IXICO will utilise its expertise to optimise, standardise and collect magnetic resonance imaging (MRI) data from specialist imaging centres across North America, Latin America, Europe, Asia and Australasia.  IXICO’s data science expertise and artificial intelligence (AI) software algorithms will be applied to provide insights into brain cellular microstructure and neuronal connectivity to support the evaluation of drug safety and efficacy.

This contract expands IXICO’s relationship with an existing client and is the fourth new contract in Huntington’s disease announced this financial year. It demonstrates the increasing adoption of IXICO’s scientific and operational expertise in this important area of clinical development; Huntington’s disease is a rare genetic neurodegenerative disorder which affects movement, cognition and behaviour.

Giulio Cerroni, CEO of IXICO, said: “I am delighted to announce this new contract for a Pivotal Phase III clinical trial with an existing client which demonstrates confidence in IXICO’s services to deliver valuable insights through our proprietary data analytics platform. Huntington’s disease is an area of significant unmet medical need as there are currently no effective marketed treatments. This latest contract award reflects our experience working in this important area of neuroscience drug development which, together with previously announced new contracts and contract extensions, provides a strong foundation for future growth.”



Source: IXICO


24 Condivisioni